Merck & Co. and BioImage sign licensing deal on Redistribution technology

Published: 14-Sep-2004

Danish company BioImage has signed a licensing agreement with Merck & Co. granting Merck the freedom to use BioImage's Redistribution technology in its drug discovery research. Financial terms were not disclosed.


Danish company BioImage has signed a licensing agreement with Merck & Co. granting Merck the freedom to use BioImage's Redistribution technology in its drug discovery research. Financial terms were not disclosed.

The Redistribution patent portfolio covers a broad range of methods aimed at studying intracellular signalling events. The technology enables high throughput screening on a number of drug discovery live cell screening applications, such as protein translocations, receptor internalisations, protein trafficking, secretions, etc. BioImage is presently out licensing the portfolio to a number of leading companies within the life science industry.

'By using the Redistribution technology, researchers can track proteins in living cells and screen for compounds that affect specific cellular signalling pathways,' said Dr Patrik Dahlen, ceo of BioImage 'This improves the biological relevance of drug screening and helps increase the speed and accuracy of drug discovery and development.

'We are delighted and proud to have a world class pharmaceutical company like Merck license our patent portfolio.'

  

You may also like